Lonza's chairman has ruled out plans to use its capacity to fill syringes and provide final production steps for new obesity drugs even as rivals scramble for a share of the booming weight-loss market. That marks a climb down from remarks at an investor event a month ago, when Albert Baehny said that Lonza would participate in the obesity therapy market thanks to its growing fill and finish capacity. The new obesity drugs, based on a class of peptides known as glucagon-like peptide-1 (GLP-1) receptor agonists, would not feature in Lonza's growth plans, despite the Swiss company producing a secondary ingredient for one such drug, Baehny said in an interview.